AUTHORS
Julia AJ Teders, Bert Van der Reijden, PhD2, Marjolein AW van den Boogert, MD, PhD3, Sonja A de Munnik, MD, PhD4, Thatjana A Gardeitchik, MD, PhD5, Bob van Gasteren6, Kimberley Bos7, Wideke Barteling8, Evelien Verwoerd9, Joop H. Jansen, Ph.D.10, Willemijn Hobo, PhD11, Aniek O De Graaf, Ph.D.12, Ian S Hitchcock, PhD13, Aoife M Magee, PhD14, Sophie J Davies, MBiol15, Nick de Jonge, MD16, Helen Warren17, Philip Dean18, Daniel Lock, PhD19, Konnie M Hebeda, MD, PhD20, Caroline MPW Mandigers, MD21, Nicolaas Schaap, MD, PhD22, Sanna R Rijpma, PhD23, Alesia Khan, MD24, Mieke WH Roeven, MD, PhD25, Anna Marneth, PhD26
AFFILIATIONS
1 Radboud University Medical Centre, Nijmegen, Netherlands
2 Radboud University Medical Centre, Nijmegen, Netherlands
3 Radboud University Medical Centre, Nijmegen, Netherlands
4 Radboud University Medical Centre, Nijmegen, Netherlands
5 Radboud University Medical Centre, Nijmegen, Netherlands
6 Radboud University Medical Centre, Nijmegen, Netherlands
7 Radboud University Medical Centre, Nijmegen, Netherlands
8 Radboud University Medical Centre, Nijmegen, Netherlands
9 Radboud University Medical Centre, Nijmegen, Netherlands
10 Radboud University Medical Centre, Nijmegen, Netherlands
11 Radboud University Medical Centre, Nijmegen, Netherlands
12 Radboud University Medical Centre, Nijmegen, Netherlands
13 University of York, York, United Kingdom
14 University of York, York, United Kingdom
15 University of York, York, United Kingdom
16 Radboud University Medical Centre, Nijmegen, Netherlands
17 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
18 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
19 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
20 Radboud University Medical Centre, Nijmegen, Netherlands
21 Canisius Wilhelmina Hospital, Nijmegen, Netherlands
22 Radboud University Medical Centre, Nijmegen, Netherlands
23 Radboud University Medical Centre, Nijmegen, Netherlands
24 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
25 Radboud University Medical Centre, Nijmegen, Netherlands
26 Radboud University Medical Centre, Nijmegen, Netherlands
ABSTRACT
Calreticulin (CALR) mutations in hematopoietic stem cells cause the myeloproliferative neoplasms (MPNs) essential thrombocythemia (ET) and myelofibrosis. Mutant CALR interacts with the thrombopoietin receptor MPL and stimulates proliferation and differentiation of megakaryocytes. This megakaryocytic proliferation results in increased platelet counts (thrombocytosis). CALR-mutated MPNs are driven by somatic mutations (primarily deletion of 52 basepairs (bp), CALRDEL52, or insertion of 5 bp, CALRINS5), causing a frameshift in the protein. Although germline CALR mutations have been described before, they were always in-frame mutations and/or not causative of MPN. Moreover, frameshift CALR mutations were found in single patients of families with MPN, but other family members with MPN did not carry this mutation. Here, we describe three families carrying frameshift CALR mutations, their clinical phenotype, and in-depth blood and bone marrow analyses.
Family members were subjected to complete blood count analyses and next-generation sequencing. Blood and bone marrow were analyzed morphologically and immunohistochemically. For CALRDUP11 families and three CALRINS5 patients, platelet granule content was studied using regular and whole-mount electron microscopy, CD62p and CD63 flow cytometry with and without TRAP-6 stimulation, platelet factor 4 (PF4) and β-thromboglobulin (β-TG) enzyme-linked immunosorbent assays, and ADP/ATP High Performance Liquid Chromatography. Cytokine-independent proliferation and downstream signaling (phospho-flow) was assessed upon lentiviral expression of an empty vector, wildtype, or mutant CALR in BA/F3-MPL cells. Equal ectopic CALR expression was validated using quantitative reverse-transcriptase polymerase chain reactions.
We found a CALR frameshift mutation caused by an 11 bp duplication (CALRDUP11) in two families, one of which was a large, four-generation family. Additionally, we found a family with a CALR frameshift mutation caused by a one bp deletion (CALRDEL1). In all mutation carriers, the mutation was present at a variant allele frequency (VAF) of ~50% and they presented with mild-to-moderate thrombocytosis (-1107x109/L). Family members without the mutations did not have thrombocytosis. Like somatic CALR mutations, CALRDUP11 and CALRDEL1 mutations are located in exon 9 and result in an MPN-characteristic mutant-specific C-terminus including a region involved in MPL binding.
We next investigated whether CALRDUP11 carriers showed platelet and megakaryocyte abnormalities resembling those reported in somatic CALR-mutated MPN. Reduced platelet α-granule content has been reported in somatic CALR-mutated patients (Kihara et al., 2020). Platelets of CALRdup11 mutation carriers had mildly reduced α- and δ-granules based on electron microscopy, CD62p and CD63 flow cytometry, and/or PF4, β-TG, and ATP/ADP content, similar to patients harboring somatic CALRINS5 mutations. Bone marrow analyses of three CALRDUP11 and two CALRDEL1 carriers showed increased and hyperlobular megakaryocytes, but no myelofibrosis. None of the mutation carriers had a history of splenomegaly, acute myeloid leukemia, or clinical phenotypes in non-hematological organs. Altogether, these findings are consistent with the phenotypes observed for ET and hereditary thrombocytosis. One of the oncogenic hallmarks of CALR-mutant MPN is cytokine-independent proliferation. Expression of CALRDUP11, CALRDELl1, CALRDEL52, and CALRINS5 caused cytokine-independent proliferation and downstream MPL signaling in BA/F3-MPL cells while control cells did not, suggesting comparable oncogenic features between somatic and germline CALR frameshift mutations.
In conclusion, our findings identify germline CALR frameshift mutations as a previously unrecognized cause of hereditary thrombocytosis through activation of canonical MPL signaling, closely resembling the clinical, cellular, and molecular hallmarks of somatic CALR-mutant disease. Since CALR is a ubiquitously expressed protein with key functions in protein-folding and calcium homeostasis, it is remarkable that we did not find any clinical phenotypes in non-hematopoietic organs. This study opens a novel avenue in understanding the biology of CALR mutations and highlights the importance of considering germline testing in case of 50% VAF in CALR-mutant patients, particularly in context of familial thrombocytosis, or prior to mutant CALR-targeted therapies.
JAJT&BAR and MWHR&AEM contributed equally.
DISCLOSURES
Anna Marneth, PhD: No relevant conflicts of interest to declare.